Visit Sanpower About Us Our Science Partner With Us Newsroom Scientific Publications Media Coverage Press Releases Join Us Contact Us Newsroom Find the latest news about our company, products, and people Scientific Publications Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens Adam S. Kibel, Brant A. Inman, et al. A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer Rana R. McKay, Jason M. Hafron, et al. Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry Oliver Sartor, Andrew J. Armstrong, et al. << 1 2 3 >> Real-World Evidence Shows Adding PROVENGE® (sipuleucel-T) to Advanced Prostate Cancer Treatment Regimen Prolonged Median Survival by 14.5 Months Significant Reduction in Death Observed in Patients Who Received Immunotherapy and Commonly Prescribed Oral Treatments, Regardless of Treatment Order Learn More Media Coverage 12.11.20 What black men need to know about prostate cancer - The Baltimore Times 10.14.20 Sipuleucel-T boosts survival versus abiraterone or enzalutamide alone in real-world mCRPC analysis - Urology Times 09.17.20 Dr. Benjamin Lowentritt discusses PROCEED registry findings with Midday Maryland 04.21.20 Multifaceted approach addresses pandemic’s threat to prostate cancer care - Urology Times 04.15.20 How is the supply chain for immunotherapies impacted by COVID-19?- BioPharma Reporter 12.07.19 For Cold Chain Tracking - Think in Color - Pharmaceutical Commerce 12.05.19 Low Disease Burden in mCRPC Improves Sipuleucel-T Survival Benefit - Renal & Urology News Show More Press Releases 06.15.21 Dendreon Pharmaceuticals Invests in Contract Manufacturing and Patient Services for Cell Therapy Partners | Business Wire 10.14.20 Real-World Evidence Shows Adding PROVENGE® (sipuleucel-T) to Advanced Prostate Cancer Treatment Regimen Prolonged Median Survival by 14.5 Months 08.05.20 Dendreon Appoints Darlene Romine as Senior Vice President of Sales and Market Access 06.08.20 Dendreon Appoints Jason O’Neill as Chief Executive Officer 05.17.20 DENDREON Initiates Phased Return to Work for All US Sites 03.19.20 DENDREON Responds to the COVID-19 Pandemic 03.12.20 Study Shows African American Men with Advanced Prostate Cancer Treated with PROVENGE® (sipuleucel-T) Live Longer than Caucasian Men 02.13.20 Real-world study of 6,000+ Medicare patients shows adding PROVENGE® (sipuleucel-T) to the mCRPC treatment regimen reduced risk of death by 45% Show More Join Us If you’re passionate about making a real difference for people living with cancer, you will be in good company. Discover Opportunities About Us Our Science Partner With Us Newsroom Join Us Contact Us Copyright © 2021 Dendreon Pharmaceuticals LLC. All Rights Reserved. PRV.0310.USA.17 Privacy Policy // Legal Notice // Medical Information // Sitemap IMPORTANT SAFETY INFORMATION INDICATION PROVENGE® (sipuleucel-T) is a prescription medicine that is used to treat certain patients with advanced prostate cancer. PROVENGE is made from your own immune cells. IMPORTANT SAFETY INFORMATION Dendreon uses cookies to analyze traffic, enhance your experience, and provide you with tailored content. By continuing to use this site, you agree with our use of cookies and our Privacy Policy. For more information, visit ourPrivacy Policy. Reject All Accept Cookies